Skip to content
Search

Sector Insights

February 2024 / EQUITY

New Diabetes and Obesity Drugs Show Promise for Patients and Investors

New Diabetes and Obesity Drugs Show Promise for Patients and Investors

New Diabetes and Obesity Drugs Show Promise...

GLP-1 treatments are poised to reshape the health care sector

By Nabil Hanano & Jeffrey Holford

By Nabil Hanano & Jeffrey Holford

January 2024 / EQUITY

Tech Tour Insights: What's Next for AI Investing?

Tech Tour Insights: What's Next for AI Investing?

Tech Tour Insights: What's Next for AI Investing?

Listen to our panel of technology portfolio managers discuss key takeaways from their...

By Multiple Authors

By Multiple Authors

October 2023 / VIDEO

Big Data and AI: Risk and Opportunity in Infrastructure Software

Big Data and AI: Risk and Opportunity in Infrastructure Software

Big Data and AI: Risk and Opportunity in...

By Sam Johnson

Sam Johnson Investment Analyst

August 2023 / VIDEO

A New Era of Gulf Aid: Potential Winners and Losers

A New Era of Gulf Aid: Potential Winners and Losers

A New Era of Gulf Aid: Potential Winners...

A new era of Gulf aid could emerge—which countries could potentially benefit, and...

By Razan Nasser

Razan Nasser Credit Analyst

June 2023 / U.S. EQUITIES

Offense and Defense—Health Care Offers Exposure to Both Worlds

Offense and Defense—Health Care Offers Exposure to Both Worlds

Offense and Defense—Health Care Offers Exposure...

Few sectors offer defensive characteristics and attractive growth potential.

By Taymour Tamaddon

Taymour Tamaddon Portfolio Manager

May 2023 / VIDEO

Medical Technology Industry Well-Positioned Post-Covid

Medical Technology Industry Well-Positioned Post-Covid

Medical Technology Industry Well-Positioned...

By Mitchell Unger

Mitchell Unger Credit Analyst

Download

Latest Date Range
Audience for the document: Share Class: Language of the document:
Download Cancel

Download

Share Class: Language of the document:
Download Cancel
Sign in to manage subscriptions for products, insights and email updates.
Once registered, you'll be able to start subscribing.

Change Details

If you need to change your email address please contact us.
Subscriptions
OK
You are ready to start subscribing.
Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. T. Rowe Price has been independently verified for the twenty four-year period ended June 30, 2020, by KPMG LLP. The verification report is available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm’s policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request

Other Literature

You have successfully subscribed.

Notify me by email when
regular data and commentary is available
exceptional commentary is available
new articles become available

Thank you for your continued interest